Literature DB >> 34283018

Sleep apnea and eye diseases: evidence of association and potential pathogenic mechanisms.

Aldara García-Sánchez1,2, Isabel Villalaín3, Mónica Asencio3, Jesús García3, Francisco García-Rio2,4,5.   

Abstract

Eye diseases are an important group of increasingly prevalent disorders that contribute very significantly to disability and represent a considerable health burden. Some data suggest that several of these diseases may be associated with sleep-disordered breathing, mainly obstructive sleep apnea (OSA), due to intermediate mechanisms, such as intermittent hypoxia or sleep fragmentation. The aims of this systematic review were to identify and critically evaluate the current evidence supporting the existence of a possible relationship between OSA and the more relevant eye diseases as well as to evaluate the potential pathogenic mechanisms. There is a body of largely low-level evidence for the association of OSA with glaucoma, nonarteritic ischemic optic neuropathy, central serous chorioretinopathy, and diabetic retinopathy. Meta-analysis of available case-control studies shows that OSA increases the risk of glaucoma (pooled odds ratio: 1.50; 95% confidence interval: 1.25 to 1.80; P < .001), nonarteritic ischemic optic neuropathy (3.62; 1.94 to 6.76; P < .001), and diabetic retinopathy (1.57; 1.09 to 2.27; P = .02). Moreover, several pathogenic pathways have been identified, mainly related to hypoxic damage, mechanical stress, systemic inflammation, oxidative stress, sympathetic tone, and endothelial dysfunction. In contrast, information about the effect of apnea-hypopnea suppression on the development and progression of eye damage is either nonexistent or of a very low level of evidence. In conclusion, OSA has emerged as an additional potential risk factor for many eye diseases, although their link is weak and contradictory, so further examination is required. CITATION: García-Sánchez A, Villalaín I, Asencio M, García J, García-Rio F. Sleep apnea and eye diseases: evidence of association and potential pathogenic mechanisms. J Clin Sleep Med. 2022;18(1):265-278.
© 2022 American Academy of Sleep Medicine.

Entities:  

Keywords:  diabetes; eye; glaucoma; intermittent hypoxia; oxidative stress; retinopathy; sleep apnea

Mesh:

Year:  2022        PMID: 34283018      PMCID: PMC8807908          DOI: 10.5664/jcsm.9552

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN: 1550-9389            Impact factor:   4.062


  117 in total

1.  Prevalence of sleep apnoea in diabetic patients.

Authors:  Anne-Katrin Schober; Markus Friedrich Neurath; Igor Alexander Harsch
Journal:  Clin Respir J       Date:  2010-06-30       Impact factor: 2.570

2.  Nonarteritic anterior ischemic optic neuropathy in patients with sleep apnea while being treated with continuous positive airway pressure.

Authors:  Raed Behbehani; Michaela K Mathews; Robert C Sergott; Peter J Savino
Journal:  Am J Ophthalmol       Date:  2005-03       Impact factor: 5.258

3.  Obstructive sleep apnoea syndrome, plasma adiponectin levels, and insulin resistance.

Authors:  Shinya Makino; Hiroshi Handa; Koji Suzukawa; Masayoshi Fujiwara; Masaharu Nakamura; Shogo Muraoka; Ikumi Takasago; Yasushi Tanaka; Kozo Hashimoto; Tamotsu Sugimoto
Journal:  Clin Endocrinol (Oxf)       Date:  2006-01       Impact factor: 3.478

4.  Obstructive sleep apnea is independently associated with insulin resistance.

Authors:  Mary S M Ip; Bing Lam; Matthew M T Ng; Wah Kit Lam; Kenneth W T Tsang; Karen S L Lam
Journal:  Am J Respir Crit Care Med       Date:  2002-03-01       Impact factor: 21.405

5.  Effects of nasal continuous positive airway pressure treatment on oxidative stress and adiponectin levels in obese patients with obstructive sleep apnea.

Authors:  Anna Myrna Jaguaribe de Lima; Clélia Maria Ribeiro Franco; Célia Maria Machado Barbosa de Castro; Alice de Andrade Bezerra; Luiz Ataíde; Alfredo Halpern
Journal:  Respiration       Date:  2009-07-03       Impact factor: 3.580

Review 6.  Obstructive sleep apnoea and cardiovascular disease.

Authors:  Manuel Sánchez-de-la-Torre; Francisco Campos-Rodriguez; Ferran Barbé
Journal:  Lancet Respir Med       Date:  2012-11-06       Impact factor: 30.700

7.  Obstructive sleep apnea in patients with central serous chorioretinopathy.

Authors:  Patrik Kloos; Irene Laube; Adelheid Thoelen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-06-11       Impact factor: 3.117

8.  The impact of bariatric surgery on retinopathy in patients with type 2 diabetes: a retrospective cohort study.

Authors:  Amin Mamoon Amin; Helen Wharton; Margaret Clarke; Ateeq Syed; Paul Dodson; Abd A Tahrani
Journal:  Surg Obes Relat Dis       Date:  2015-10-01       Impact factor: 4.734

9.  Sleep apnoea in diabetic patients with autonomic neuropathy.

Authors:  P J Rees; J G Prior; G M Cochrane; T J Clark
Journal:  J R Soc Med       Date:  1981-03       Impact factor: 18.000

10.  Sleep apnea syndrome represents a risk for glaucoma in a veterans' affairs population.

Authors:  Megan Boyle-Walker; Leo P Semes; Olivio J Clay; Lei Liu; Patti Fuhr
Journal:  ISRN Ophthalmol       Date:  2011-11-17
View more
  3 in total

1.  The association between sleep disorders, employment, and income among adults in the United States.

Authors:  Phillip Huyett; Neil Bhattacharyya
Journal:  J Clin Sleep Med       Date:  2022-08-01       Impact factor: 4.324

2.  Evaluation of retinal nerve fiber layer, ganglion cell layer, and optic nerve head morphological parameters in patients with obstructive sleep apnea and comparison with normal population.

Authors:  Vandhana Sundaram; Sujithra Haridas; Meenakshi Dhar; C P Harikrishnan
Journal:  Indian J Ophthalmol       Date:  2022-02       Impact factor: 2.969

3.  Diurnal changes of retinal microvascular circulation and RNFL thickness measured by optical coherence tomography angiography in patients with obstructive sleep apnea-hypopnea.

Authors:  Yi Cai; Wen-Bo Liu; Miao Zhou; Yu-Tong Jin; Guo-Sheng Sun; Long Zhao; Fang Han; Jin-Feng Qu; Xuan Shi; Ming-Wei Zhao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-09       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.